Investors piled into Elevate Uranium on Tuesday after the Australian-listed explorer released pilot-plant data showing its proprietary ore-sorting technology can dramatically concentrate low-grade uranium feed before the costly chemical processing stage even begins.
The company’s shares jumped 15% to €0.1876 in European trading, extending a rally that has pushed the equity roughly 25% above its 50-day moving average. The market capitalization now stands at €85.84 million.
A Sevenfold Grade Lift From Physical Separation
The results, generated at a demonstration facility in Namibia, cover the first four stages of the U-pgrade™ flowsheet deployed at the Marenica project, in which Elevate holds a 90% interest. Those initial process steps rejected approximately 88% of the incoming ore mass as barren rock, while uranium head grades climbed from 89 parts per million to 590 ppm — a sevenfold enrichment achieved through purely mechanical and physical separation techniques.
Crucially, the process recovered 79% of the contained uranium into the concentrate stream destined for the final processing stage. That combination of mass rejection and high recovery matters because Marenica’s resource base, while substantial at 52.8 million pounds of U3O8, carries average grades of only around 180 ppm. Slashing the volume of material that must move through downstream leaching and metal-recovery circuits materially improves the project’s prospective economics.
Final Flotation Stage Now in the Spotlight
With the first four phases validated, attention shifts to the fifth and final step: a flotation unit that was commissioned in August and is currently being optimized. Management wants to bring the circuit into steady-state operation to generate reliable data across the fully integrated flowsheet, which market participants view as the decisive test of the technology’s industrial scalability.
Full results from all five stages are expected in the quarter ending December 2026, and those figures are anticipated to underpin feasibility work and a potential path toward commercial development.
Should investors sell immediately? Or is it worth buying Elevate Uranium?
Sector Tailwinds From Washington to the Spot Market
The operational progress arrives as the uranium sector enjoys a broadly supportive backdrop. Spot prices recently touched their highest level since February, with September futures trading at $88.15 per pound. That pricing strength is buttressing valuations across the exploration and development spectrum.
Geopolitical dynamics are also working in Namibia’s favor. A $2.7 billion US funding program aimed at reducing reliance on imported nuclear fuel has put African supply sources firmly on Washington’s radar. Namibia, which supplied roughly 4% of US requirements last year, features prominently alongside Niger and South Africa in these efforts — even as Chinese interests retain significant stakes in major local operations such as Husab and Rössing.
The competitive landscape is heating up accordingly. Deep Yellow is weighing financing options for its Tumas project, targeting a final investment decision in the fourth quarter of this year. Elsewhere, NexGen Energy is reportedly in regular discussions with BHP regarding its Rook I project and is seeking to raise around $1 billion over the next nine months.
Analyst Recalibration Reflects Shifting Sentiment
Brokerage Morgans has recently refreshed its views on several uranium names, trimming Paladin Energy from “Buy” to “Accumulate” while holding its price target at A$14.10 — still above the current trading level. The revisions signal growing confidence in the long-term viability of emerging producers across the region.
For Elevate, Tuesday’s move marks a notable technical breakout, with the stock now trading well above its trend indicators. The decisive factor for the share price going forward, however, remains the outcome of the final flotation test results due before year-end — the data point that will ultimately determine whether U-pgrade™ can translate pilot-scale promise into a bankable commercial proposition.
Ad
Elevate Uranium Stock: Buy or Sell?! New Elevate Uranium Analysis from September 1 delivers the answer:
The latest Elevate Uranium figures speak for themselves: Urgent action needed for Elevate Uranium investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from September 1.
Elevate Uranium: Buy or sell? Read more here...
